ANDA 205236, held by Sciegen Pharms. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 205236 (Hydralazine Hydrochloride), held by Sciegen Pharms, was first approved by FDA on May 26, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 26, 2017 | Original application | Approved | None posted |
| Hydralazine Hydrochloride10MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Hydralazine Hydrochloride25MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Hydralazine Hydrochloride50MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Hydralazine Hydrochloride100MG · tablet;oral | Hydralazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters